MENU 简体中文ENG
Innovations
Innovations
AAVneO™ System:Next-Generation Capsid Screening Platform
AAVneO™ System:Next-Generation Capsid Screening Platform
Our AAVneO™ system uses in-vivo direct evolution and high-throughput screening to discover the next-generation adeno-associated viral vectors with enhanced targeting ability, improved payload size, lower immunogenicity, and superior manufacturability.Scientists at OBiO have constructed the 7-mers mutagenesis libraries for AAV serotypes with billion-level library abundance. AAVneO™ will serve as an integrated platform that enables gene therapy developers to screen, select, and co-develop the next-generation vectors for a broad range of diseases and overcome the limitations of conventional AAV-based gene therapies.
OVersatileTM Platform: Versatility for Various Needs
OVersatileTM Platform: Versatility for Various Needs
Comprehensive process development capabilities are the critical determinant to fulfill the various development and manufacturing needs. Our OVersatilie™ process development platform aims to offer an integrated solutions for various gene and cell therapy product. The platform covers cell factories, fixed bed bioreactors, dissolvable microcarriers, and roller bottles for adherent cell culture process, the large-scale, serum-free suspension cell culture process, and conventional cell lines including 293-based cells, Vero cells, and HeLa cells. Process development experts at OBiO will assist you to diagnose the manufacturing gaps, optimize the parameters with the versatile platform, and de-risk your industrialization process.
Proprietary Cell Line Development: High-Yielding Cell Line for Suspension Culture
Proprietary Cell Line Development: High-Yielding Cell Line for Suspension Culture
Discovering a stable and high-yield cell line is a consistent goal for a CDMO solution provider. Our experienced research team dedicates to the development of proprietary high-yielding cell clones and optimizing the cell culture process and media formulation. At the current stage, our team has obtained a single-cell derived clone for AAV suspension culture with 30% to 50% improvement in viral titer compared to the conventional HEK293 cells. We will keep progressing on the screening process of a single-cell derived clone with superior performance.
CONTACT US
First Name*
Last Name*
Company*
Email*
Phone Number*
I'm interested in…
Questions or Comments
Security Code*
I AGREE*
By submitting this form I agree that OBiO may process my data in the manner described in OBiO’s Privacy Policy
We won’t share your information.
Upcoming Events
© 2022 OBiO Technology (Shanghai) Corp., Ltd. All Rights Reserved